These studies show that an effective dose can be achieved as early as 1) cost.

In clinical trials supporting the FDA submission and the investigational once-daily formulation demonstrated an effective dose range of Seroquel SR of 400-800 mg / day In addition, these studies show that an effective dose can be achieved as early as 1) cost . 1).

AstraZeneca is a major international healthcare company in the intervention is research, development, manufacture and marketing of prescription pharmaceuticals and healthcare services. The FTSE4Good Index. Of the world’s leading pharmaceutical companies with sales of $ 23950000000 and leading positions in sales of gastrointestinal oncology cardiovascular, respiratory, neuroscience, oncology and infection products. AstraZeneca is listed in the Dow Jones Sustainability Index as well as the FTSE4Good Index. ‘ Arimidex ‘ UK Summary of Product Characteristics 30 June 2006 2 ATAC Trialists’ Group. Results of the ATAC trial after completion of 5 years of adjuvant therapy for breast cancer. 365 : 60-62. Jakesz R et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005, 366: 455-462 4th Boccardo F, et al. The switch to anastrozole compared with tamoxifen further treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole trial. J Clin Oncol 2005, 23: 5138-5147. Boccardo F, et al.

All statements that are are not historical facts are included in this press release are forward-looking statements that are subject risks and uncertainties, forward looking reproductions has ability to succeed in the clinical development of its technology, which date of notification and publication of data in these includes clinical trial and the precision of these studies, limited populations the Clinical studies to and the possibility of that the definitive data may not comply with preliminary data, reproductions ‘ ability to raise additional capital in the a timely manner and on acceptable terms or even and increasing different risk, to 31 in the company’s Annual Report on Form 10 – C for the year December 2006 repro ‘ Quarterly Reports on Form 10 – Q for the quarters 31 In Jun. Identified, and 30 September 2007, as they are submitted from society Exchange Act documents occasionally update to time. These documents may be upon request from Repros Therapeutics declines Reproduction and any intent or obligation to update or revise any forward-looking statement, whether as. Than result of new information, future events or otherwise.

Other entries from category "slimming":

Tag Cloud